Strs Ohio Invests $61,000 in Affimed NV (NASDAQ:AFMD)

Strs Ohio acquired a new position in shares of Affimed NV (NASDAQ:AFMD) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 20,800 shares of the biopharmaceutical company’s stock, valued at approximately $61,000.

Several other institutional investors also recently bought and sold shares of the company. State of New Jersey Common Pension Fund D purchased a new stake in shares of Affimed during the second quarter worth $29,000. Parametric Portfolio Associates LLC purchased a new stake in shares of Affimed during the second quarter worth $41,000. Meeder Asset Management Inc. purchased a new stake in shares of Affimed during the third quarter worth $47,000. Mackenzie Financial Corp purchased a new stake in shares of Affimed during the second quarter worth $47,000. Finally, JPMorgan Chase & Co. purchased a new position in Affimed in the second quarter valued at $47,000. 51.01% of the stock is currently owned by institutional investors and hedge funds.

AFMD has been the topic of several recent analyst reports. Zacks Investment Research lowered Affimed from a “buy” rating to a “hold” rating in a report on Thursday, August 8th. ValuEngine raised Affimed from a “sell” rating to a “hold” rating in a report on Wednesday, August 28th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Affimed currently has a consensus rating of “Buy” and an average target price of $6.36.

NASDAQ:AFMD opened at $2.89 on Friday. The business’s fifty day moving average price is $2.98 and its 200 day moving average price is $3.04. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.48 and a quick ratio of 3.47. Affimed NV has a 12 month low of $2.52 and a 12 month high of $5.08.

Affimed (NASDAQ:AFMD) last posted its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.16) EPS for the quarter, meeting the consensus estimate of ($0.16). The firm had revenue of $4.50 million for the quarter, compared to analyst estimates of $6.46 million. Affimed had a negative return on equity of 30.94% and a negative net margin of 30.87%. As a group, equities research analysts predict that Affimed NV will post -0.08 EPS for the current year.

Affimed Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.

See Also: Most Volatile Stocks

Want to see what other hedge funds are holding AFMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Affimed NV (NASDAQ:AFMD).

Institutional Ownership by Quarter for Affimed (NASDAQ:AFMD)

Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.